ARCHIVES

In Brief: What’s In A Name? DRCCA Doesn’t Do It; O’Conor Says ICRDB Program Should Consider New Challenges

This article is from The Cancer Letter archive.

Vol. 06 No. 39 | October 3, 1980

Download PDF Visit The Full Archive

Related Articles

Harvard’s DePinho Becomes Finalist at MD Anderson

May 20, 2011

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

ASCO 2011 Award Winners

June 10, 2011

BioSeek Awarded NIH SBIR For Compound Validation.

July 4, 2003

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

May 27, 2005

“The One Thing You Want From AN NCI Director: He Will Be Bound By The Facts”

October 28, 1994